Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380401 · ClinicalTrials.gov registry record · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
A NA study of Premature, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- NA
- Development phase
- 328
- Enrollment target
- 7
- Study locations
NCT05380401: Recruiting NA study of Premature, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05380401 is a NA study of Premature that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 328 participants, above the 153-participant average among 4 other Premature trials with a reported enrollment target (114% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05380401, a NA study of Premature, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- NA
- Development phase
- 328 participants
- Enrollment target
- 7
- Study locations
Study Summary
A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
Primary Outcome
Change in lipid metabolites reflected by levels in plasma
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Enfamil® DHA & ARA Supplement for Special Dietary Use
Study Locations (7)
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- Northwestern University - Chicago
Texas
- University Health System - San Antonio
- University of Texas Health Science Center at San Antonio - San Antonio
California
- University of California, Los Angeles (UCLA) - Los Angeles
Connecticut
- Yale New Haven Hospital - New Haven
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2028-04 |
| Phase | NA |
What NCT05380401 shows while recruiting
NCT05380401 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, above the 153-participant average among 4 other Premature trials with a reported enrollment target (114% higher).
The record links to 1 condition, with Premature appearing as the primary indexed condition, and to 1 intervention - of which Enfamil® DHA & ARA Supplement for Special Dietary Use is the first listed.
NCT05380401 lists 7 locations in 5 states (Illinois, Texas, California).
Frequently Asked Questions
What is clinical trial NCT05380401 about?
NCT05380401 is a clinical study titled "Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants". A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
What is the current status of trial NCT05380401?
This trial is currently recruiting. It is a NA study. The enrollment target is 328 participants. The study started on 2023-03-09. Estimated completion is 2028-04.
What conditions does trial NCT05380401 study?
This clinical trial studies the following conditions: Premature.
What interventions are being tested in trial NCT05380401?
The interventions under investigation include: Enfamil® DHA & ARA Supplement for Special Dietary Use (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05380401?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05380401 being conducted?
This trial has 7 study locations across California, Connecticut, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
RECRUITING · NA
-
Baby ABS (Abdominal Binder Study)
RECRUITING · NA
-
Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates
RECRUITING
-
Growing Little PEAPODS Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI